These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10960870)

  • 1. Non-parametric maximum likelihood estimators for disease mapping.
    Biggeri A; Marchi M; Lagazio C; Martuzzi M; Böhning D
    Stat Med; 2000 Sep 15-30; 19(17-18):2539-54. PubMed ID: 10960870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parametric bootstrap and penalized quasi-likelihood inference in conditional autoregressive models.
    MacNab YC; Dean CB
    Stat Med; 2000 Sep 15-30; 19(17-18):2421-35. PubMed ID: 10960863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A general maximum likelihood analysis of variance components in generalized linear models.
    Aitkin M
    Biometrics; 1999 Mar; 55(1):117-28. PubMed ID: 11318145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [State of health of populations residing in geothermal areas of Tuscany].
    Minichilli F; Nuvolone D; Bustaffa E; Cipriani F; Vigotti MA; Bianchi F
    Epidemiol Prev; 2012; 36(5 Suppl 1):1-104. PubMed ID: 23139155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Random effects models with non-parametric priors.
    Butler SM; Louis TA
    Stat Med; 1992; 11(14-15):1981-2000. PubMed ID: 1480884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatial variation of mortality for common and rare cancers in Piedmont, Italy, from 1980 to 2000: a Bayesian approach.
    Maule M; Merletti F; Mirabelli D; La Vecchia C
    Eur J Cancer Prev; 2006 Apr; 15(2):108-16. PubMed ID: 16523007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling spatial disease rates using maximum likelihood.
    Leroux BG
    Stat Med; 2000 Sep 15-30; 19(17-18):2321-32. PubMed ID: 10960856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of spatio-temporal models for the estimation of the mortality relative risk from breast cancer in Galicia, Spain.
    López-Vizcaíno ME; Vidal-Rodeiro CL; Santiago-Pérez MI; Vázquez-Fernández E; Hervada-Vidal X
    J Cancer Epidemiol Prev; 2002; 7(4):181-93. PubMed ID: 12846489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical issues in the analysis of disease mapping data.
    Pascutto C; Wakefield JC; Best NG; Richardson S; Bernardinelli L; Staines A; Elliott P
    Stat Med; 2000 Sep 15-30; 19(17-18):2493-519. PubMed ID: 10960868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease mapping models: an empirical evaluation. Disease Mapping Collaborative Group.
    Lawson AB; Biggeri AB; Boehning D; Lesaffre E; Viel JF; Clark A; Schlattmann P; Divino F
    Stat Med; 2000 Sep 15-30; 19(17-18):2217-41. PubMed ID: 10960849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation.
    Launay-Iliadis MC; Bruno R; Cosson V; Vergniol JC; Oulid-Aissa D; Marty M; Clavel M; Aapro M; Le Bail N; Iliadis A
    Cancer Chemother Pharmacol; 1995; 37(1-2):47-54. PubMed ID: 7497596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis by random effect modelling in generalized linear models.
    Aitkin M
    Stat Med; 1999 Sep 15-30; 18(17-18):2343-51. PubMed ID: 10474144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploratory tools for disease mapping in geographical epidemiology.
    Cislaghi C; Biggeri A; Braga M; Lagazio C; Marchi M
    Stat Med; 1995 Nov 15-30; 14(21-22):2363-81. PubMed ID: 8711275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-goal estimates for disease mapping.
    Shen W; Louis TA
    Stat Med; 2000 Sep 15-30; 19(17-18):2295-308. PubMed ID: 10960854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expectation maximization-based likelihood inference for flexible cure rate models with Weibull lifetimes.
    Balakrishnan N; Pal S
    Stat Methods Med Res; 2016 Aug; 25(4):1535-63. PubMed ID: 23740876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hierarchical Bayesian approach to age-specific back-calculation of cancer incidence rates.
    Mezzetti M; Robertson C
    Stat Med; 1999 Apr; 18(8):919-33. PubMed ID: 10363331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonparametric estimation of ROC curves in the absence of a gold standard.
    Zhou XH; Castelluccio P; Zhou C
    Biometrics; 2005 Jun; 61(2):600-9. PubMed ID: 16011710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease mapping using empirical Bayes and Bayes methods on mortality statistics in The Netherlands.
    Heisterkamp SH; Doornbos G; Gankema M
    Stat Med; 1993 Oct; 12(19-20):1895-913. PubMed ID: 8272669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.